Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

interleukin-12-Fc fusion protein DF6002

A fusion protein composed of human Interleukin-12 (IL-12) fused to a Fc fragment, with potential immunomodulatory and antineoplastic activities. Although the exact mechanism of action has not been completely characterized, upon administration, the IL-12 moiety binds to the IL-12 receptor. This may activate the immune system by promoting the secretion of interferon-gamma, activating natural killer cells (NKs), and inducing cytotoxic T-lymphocyte (CTL) responses, which may result in both decreased tumor cell proliferation and enhanced immune-mediated destruction of tumor cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	IL12-Fc fusion protein DF6002
Code name:	DF 6002 DF-6002 DF6002

interleukin-12-Fc fusion protein DF6002

Search NCI's Drug Dictionary